Literature DB >> 15794826

Proton magnetic resonance spectroscopic imaging integrated into image-guided surgery: correlation to standard magnetic resonance imaging and tumor cell density.

Oliver Ganslandt1, Andreas Stadlbauer, Rudolf Fahlbusch, Kyosuke Kamada, Rolf Buslei, Ingmar Blumcke, Ewald Moser, Christopher Nimsky.   

Abstract

OBJECTIVE: In this study, we attempted to improve the delineation of the infiltration zone in gliomas using proton magnetic resonance spectroscopic imaging (1H MRSI). In conventional magnetic resonance imaging (MRI), the boundaries of gliomas sometimes are underestimated. 1H MRSI is a noninvasive tool that can be used to investigate the spatial distribution of metabolic changes in brain lesions. The purpose was to correlate tumor cell density from histopathological specimens with metabolic levels and the coregistered metabolic maps.
METHODS: We developed a method to integrate spectroscopic data depicted as metabolic maps of biochemically pathological tissue into frameless stereotaxy. In seven patients harboring gliomas, we performed 1H MRSI with high spatial resolution and evaluated the spectral data. An algorithm was developed for user-independent calculation of pathological voxels and for visualization as metabolic maps. These maps were integrated into a three-dimensional MRI data set used for frameless stereotaxy. Stereotactic biopsies were taken from three different areas in and around the tumor involving the maximum pathological change, the border zone, and an area from outside the spectroscopically suspicious area. These specimens were correlated to the exact voxel positions in the stereotactic image space and evaluated histopathologically.
RESULTS: In all cases, the implementation of the metabolic maps into frameless stereotaxy was successful, and stereotactic biopsies were acquired by use of the spectral data. A relation could be demonstrated between the metabolic changes and tumor cell density ranging from 60 to 100% in the maximum pathological area to 5 to 15% in the border zone. Interestingly, the tumor areas defined by the metabolic maps and histopathologically confirmed by biopsy exceeded the T2-weighted signal change in all cases, ranging from 6 to 32% in the examined volume.
CONCLUSION: Our preliminary data suggest that 1H MRSI may be useful in combination with frameless stereotaxy to define more exactly the tumor infiltration zone in glioma surgery compared with conventional anatomic MRI alone.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15794826     DOI: 10.1227/01.neu.0000156782.14538.78

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  17 in total

1.  Clinical target volume delineation in glioblastomas: pre-operative versus post-operative/pre-radiotherapy MRI.

Authors:  P Farace; M G Giri; G Meliadò; D Amelio; L Widesott; G K Ricciardi; S Dall'Oglio; A Rizzotti; A Sbarbati; A Beltramello; S Maluta; M Amichetti
Journal:  Br J Radiol       Date:  2010-11-02       Impact factor: 3.039

2.  The relationship between Cho/NAA and glioma metabolism: implementation for margin delineation of cerebral gliomas.

Authors:  Jun Guo; Chengjun Yao; Hong Chen; Dongxiao Zhuang; Weijun Tang; Guang Ren; Yin Wang; Jinsong Wu; Fengping Huang; Liangfu Zhou
Journal:  Acta Neurochir (Wien)       Date:  2012-06-23       Impact factor: 2.216

Review 3.  Image guidance and neuromonitoring in neurosurgery.

Authors:  Wai Hoe Ng; Karim Mukhida; James T Rutka
Journal:  Childs Nerv Syst       Date:  2010-02-20       Impact factor: 1.475

4.  Biopsy targeting with dynamic contrast-enhanced versus standard neuronavigation MRI in glioma: a prospective double-blinded evaluation of selection benefits.

Authors:  Vera C Keil; Bogdan Pintea; Gerrit H Gielen; Susanne Greschus; Rolf Fimmers; Jürgen Gieseke; Matthias Simon; Hans H Schild; Dariusch R Hadizadeh
Journal:  J Neurooncol       Date:  2017-04-19       Impact factor: 4.130

5.  A generative approach for image-based modeling of tumor growth.

Authors:  Bjoern H Menze; Koen Van Leemput; Antti Honkela; Ender Konukoglu; Marc-André Weber; Nicholas Ayache; Polina Golland
Journal:  Inf Process Med Imaging       Date:  2011

6.  Hypercellularity Components of Glioblastoma Identified by High b-Value Diffusion-Weighted Imaging.

Authors:  Priyanka P Pramanik; Hemant A Parmar; Aaron G Mammoser; Larry R Junck; Michelle M Kim; Christina I Tsien; Theodore S Lawrence; Yue Cao
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-03-26       Impact factor: 7.038

Review 7.  MRS and MRSI guidance in molecular medicine: targeting and monitoring of choline and glucose metabolism in cancer.

Authors:  Kristine Glunde; Lu Jiang; Siver A Moestue; Ingrid S Gribbestad
Journal:  NMR Biomed       Date:  2011-07       Impact factor: 4.044

Review 8.  Imaging of brain tumors: MR spectroscopy and metabolic imaging.

Authors:  Alena Horská; Peter B Barker
Journal:  Neuroimaging Clin N Am       Date:  2010-08       Impact factor: 2.264

9.  PET/MRI in cancer patients: first experiences and vision from Copenhagen.

Authors:  Andreas Kjær; Annika Loft; Ian Law; Anne Kiil Berthelsen; Lise Borgwardt; Johan Löfgren; Camilla Bardram Johnbeck; Adam Espe Hansen; Sune Keller; Søren Holm; Liselotte Højgaard
Journal:  MAGMA       Date:  2012-12-25       Impact factor: 2.310

Review 10.  Quantitative imaging biomarkers in neuro-oncology.

Authors:  Adam D Waldman; Alan Jackson; Stephen J Price; Christopher A Clark; Thomas C Booth; Dorothee P Auer; Paul S Tofts; David J Collins; Martin O Leach; Jeremy H Rees
Journal:  Nat Rev Clin Oncol       Date:  2009-06-23       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.